NDV-HXP-S
AXP000209.1 · Vaccine
- Platform
- Newcastle disease virus (LaSota) vector
- Targets
- SARS-CoV-2 S
- Originator
- Icahn School of Medicine at Mount Sinai
- Sponsor
- Laboratorio Avi-Mex (Avimex)
Names
| Name | Type | Source |
|---|---|---|
| NDV-HXP-S | preferred name, code | curator, paper |
| Patria | brand | press |
| ButanVac ambiguous | synonym | curator |
| HXP-GPOVac ambiguous | synonym | curator |
Virus
- Role
- Vaccine vector
- Family
- Paramyxoviridae
- Virus
- Newcastle disease virus (NCBI Taxonomy 2560319)
- Strain
- LaSota
- Replication
- replicating
- Modifications
- SARS-CoV-2 spike ectodomain with six stabilising proline mutations (HexaPro) and a deleted polybasic cleavage site, fused to the NDV fusion protein transmembrane and cytoplasmic domains
- Transgenes
- SARS-CoV-2 spike (HexaPro)
- Route
- intramuscular, intranasal
- Source
- evidence
Approvals
| Agency | Region | Date | Status | Brand | Indication | Source |
|---|---|---|---|---|---|---|
| other | MX | 2024-06 | conditional | Patria | Emergency-use authorisation as a COVID-19 vaccine | source |
Clinical trials (6)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT07215520 | Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults | Active not recruiting | Phase 2 | 2025-11-03 | 2026-09-06 | 200 | COVID-19 |
| NCT05354024 | Phase II/III Randomized Clinical Trial of Booster Dose of COVID-19 (Recombinant, Inactivated) Vaccine | Completed | Phase 2/3 | 2023-02-28 | 2023-10-05 | 4400 | Coronavirus Infections; Healthy |
| NCT05181709 | A Live Recombinant Newcastle Disease Virus-vectored COVID-19 Vaccine Phase 1 Study. | Completed | Phase 1 | 2022-02-09 | 2023-05-03 | 35 | SARS-CoV-2 |
| NCT05940194 | NDV-HXP-S Vaccine Clinical Trial (COVIVAC) | Completed | Phase 2 | 2021-08-11 | 2021-10-18 | 374 | COVID-19 |
| NCT04993209 | Clinical Trial of the COVID-19 Vaccine (Recombinant, Inactivated) in Brazil | Completed | Phase 1 | 2021-07-09 | 2021-12-10 | 320 | Coronavirus Infections; Healthy |
| NCT04764422 | Assess the Safety and Immunogenicity of NDV-HXP-S Vaccine in Thailand | Completed | Phase 1/2 | 2021-03-20 | 2022-09-12 | 455 | Covid-19; Covid-19 Vaccine; Pneumonia, Viral; SARS Pneumonia |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 42378814 | Phase 1 trial of intranasal NDV-HXP-S in previously vaccinated adults. | Vaccine | 2026 | cited by trial NCT05181709 |
| PMID 39527880 | Phase II study on the safety and immunogenicity of single-dose intramuscular or intranasal administration of the AVX/COVID-12 "Patria" recombinant Newcastle disease virus vaccine as a heterologous booster against COVID-19 in Mexico. | Vaccine | 2025 | name in title: Patria |
| PMID 39615342 | Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: A randomised, comparator-controlled, phase 2 trial. | Vaccine | 2025 | cited by trial NCT05940194 |
| PMID 39667115 | A single immunization with intranasal Newcastle disease virus (NDV)-based XBB.1.5 variant vaccine reduces disease and transmission in animals against matched-variant challenge. | Vaccine | 2025 | cited by trial NCT05181709 |
| PMID 40037239 | Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Results of a randomized vaccine-controlled phase I ADAPTCOV trial in Brazil. | Vaccine | 2025 | cited by trial NCT04993209 |
| PMID 36435633 | Nasal vaccines: solutions for respiratory infectious diseases. | Trends in molecular medicine | 2023 | cited by trial NCT05354024 |
| PMID 35284808 | Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial. | EClinicalMedicine | 2022 | cited by trial NCT04764422 |
| PMID 35577631 | Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam. | Vaccine | 2022 | name in abstract: NDV-HXP-S |
| PMID 34580673 | Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomised, Placebo-Controlled, Phase 1/2 Trial. | medRxiv : the preprint server for health sciences | 2021 | cited by trial NCT04764422 |
Unconfirmed matches (1)
Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 42869875 | Safety and immunogenicity of Thailand Government Pharmaceutical Organization (GPO) produced, COVID-19 vaccine, 10 μg HXP-GPOVac: A Phase III, double-blind, randomized trial in comparison with VAXZEVRIA. | Vaccine | 2026 | name in title: HXP-GPOVac |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41288394 | Development of an RT-qPCR and a Next-Generation Sequencing approach to assess viral shedding of NDV-based SARS-CoV-2 variant vaccines. | Microbiology spectrum | 2026 | name in abstract: NDV-HXP-S |
| PMID 41746060 | AddaVax, AddaS03, and Alum Effectively Enhance Cross-Reactive and Cross-Neutralizing Antibody Responses Against SARS-CoV-2 Induced by the Inactivated NDV-HXP-S Vaccine in Mice. | Vaccines | 2026 | name in title: NDV-HXP-S |
| PMID 41926837 | COVID-19 in Latin America: Clinical and immunological insights, vaccine development, and lessons for pandemic preparedness. | Seminars in immunology | 2026 | name in abstract: Patria |
| PMID 42347602 | Safety and Immunogenicity of a Locally Produced Inactivated NDV-HXP-S COVID-19 Vaccine (HXP-GPOVac) Compared with BNT162b2: A Phase II Randomized, Controlled, Double-Blind Noninferiority Trial in Thai Adults. | Vaccines | 2026 | name in title: NDV-HXP-S |
| PMID 42646679 | Safety and Immunogenicity of an Additional Dose of Thailand Government Pharmaceutical Organization (GPO) Inactivated NDV-HXP-S COVID-19 Vaccine (HXP-GPOVac) Administered After Primary Vaccination with HXP-GPOVac or BNT162b2: An Open-Label Phase II Extension Trial in Thai Adults. | Vaccines | 2026 | name in title: NDV-HXP-S |
| PMID 42943471 | Systemic T-Cell Activation Landscapes Elicited Following Intramuscular and Intranasal Immunization with the Active NDV-Vectored Anti-COVID-19 Vaccine "Patria" in Humans. | Microorganisms | 2026 | name in title: Patria |
| PMID 42955440 | Environmental monitoring of the Lagoon of Lake Patria in South Tyrrhenian sea, Italy. | Environmental monitoring and assessment | 2026 | name in title: Patria |
| PMID 40165947 | Mucosal multivalent NDV-based vaccine provides cross-reactive immune responses against SARS-CoV-2 variants in animal models. | Frontiers in immunology | 2025 | name in abstract: NDV-HXP-S |
| PMID 40241155 | Navigating authoritarian politics: towards reflexive framing in healthcare research. | Globalization and health | 2025 | name in abstract: Patria |
| PMID 40458417 | Addressing SARS-CoV-2 evolution: neutralization of emerging variants of concern by the AVX/COVID-12 'Patria' vaccine based on HexaPro-S ancestral Wuhan spike or its updated BA.2.75.2 version. | Frontiers in immunology | 2025 | name in title: Patria |
| PMID 40789265 | Immune responses to a heterologous booster with mRNA based COVID-19 vaccine after priming with an inactivated Newcastle disease virus recombinant vaccine expressing the SARS-CoV-2 spike protein (NDV-HXP-S). | Vaccine | 2025 | name in title: NDV-HXP-S |
| PMID 41271759 | Immunogenicity and efficacy of homologous and heterologous NDV and MVA SARS-CoV-2 vaccines in mice and hamsters. | NPJ vaccines | 2025 | name in abstract: NDV-HXP-S |
| PMID 41290704 | One year follow up of phase 1/2 randomized, placebo controlled trial of NDV-HXP-S vaccine in Thailand. | NPJ vaccines | 2025 | name in title: NDV-HXP-S |
| PMID 38369699 | Effect of homologous or heterologous vaccine booster over two initial doses of inactivated COVID-19 vaccine. | Expert review of vaccines | 2024 | name in abstract: NDV-HXP-S |
| PMID 38372198 | Development of a quantitative ELISA for SARS-CoV-2 vaccine candidate, NDV-HXP-S, with CpG 1018® adjuvant. | Human vaccines & immunotherapeutics | 2024 | name in title: NDV-HXP-S |
| PMID 38848648 | Intranasal SARS-CoV-2 Omicron variant vaccines elicit humoral and cellular mucosal immunity in female mice. | EBioMedicine | 2024 | name in abstract: NDV-HXP-S |
| PMID 39189025 | Development of multidose thermotolerant formulations of a vector-based Covid-19 vaccine candidate, NDV-HXP-S in different product formats: Stability and preservative efficacy study. | Vaccine: X | 2024 | name in title: NDV-HXP-S |
| PMID 36791207 | An inactivated NDV-HXP-S COVID-19 vaccine elicits a higher proportion of neutralizing antibodies in humans than mRNA vaccination. | Science translational medicine | 2023 | name in title: NDV-HXP-S |
| PMID 37164959 | Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico. | NPJ vaccines | 2023 | name in abstract: NDV-HXP-S |
| PMID 34520260 | "Un abrazo a la distancia": An Exploration of Spanish-Speaking Women's Experiences with Pregnancy and Social Isolation in an Urban U.S. Setting. | Hispanic health care international : the official journal of the National Association of Hispanic Nurses | 2022 | name in abstract: Patria |
| PMID 35169806 | Safety and immunogenicity of a live recombinant Newcastle disease virus-based COVID-19 vaccine (Patria) administered via the intramuscular or intranasal route: Interim results of a non-randomized open label phase I trial in Mexico. | medRxiv : the preprint server for health sciences | 2022 | name in title: Patria |
| PMID 35263331 | Prevalence rate and risk factors of human cystic echinococcosis: A cross-sectional, community-based, abdominal ultrasound study in rural and urban north-central Chile. | PLoS neglected tropical diseases | 2022 | name in abstract: Patria |
| PMID 35350201 | Trivalent NDV-HXP-S vaccine protects against phylogenetically distant SARS-CoV-2 variants of concern in mice. | bioRxiv : the preprint server for biology | 2022 | name in title: NDV-HXP-S |
| PMID 35658571 | Trivalent NDV-HXP-S Vaccine Protects against Phylogenetically Distant SARS-CoV-2 Variants of Concern in Mice. | Microbiology spectrum | 2022 | name in title: NDV-HXP-S |
| PMID 33903511 | Notes on some Tanzanian butterfly specimens in the Suffert Collection: a case of patria/ falsa/. | Zootaxa | 2021 | name in title: Patria |
| PMID 34544278 | Safety and Immunogenicity of a Newcastle Disease Virus Vector-Based SARS-CoV-2 Vaccine Candidate, AVX/COVID-12-HEXAPRO (Patria), in Pigs. | mBio | 2021 | name in title: Patria |
| PMID 34707161 | A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses. | Nature communications | 2021 | name in abstract: NDV-HXP-S |
| PMID 34868082 | Safety and Immunogenicity Analysis of a Newcastle Disease Virus (NDV-HXP-S) Expressing the Spike Protein of SARS-CoV-2 in Sprague Dawley Rats. | Frontiers in immunology | 2021 | name in title: NDV-HXP-S |
| PMID 33399661 | [Epidemiology of Chagas disease: high mortality and incidence rate, Coquimbo Region]. | Revista chilena de infectologia : organo oficial de la Sociedad Chilena de Infectologia | 2020 | name in abstract: Patria |
| PMID 31460517 | Prof. Dr. Gheorghe Bilaşcu. Pro patria. | Medicine and pharmacy reports | 2019 | name in title: Patria |
| PMID 28943445 | The effects of Cissampelos pareira extract on envenomation induced by Bothropsdiporus snake venom. | Journal of ethnopharmacology | 2018 | name in abstract: Patria |
| PMID 28898336 | [Analysis of human cyst echinococcosis in a northern Chilean region from 2008 to 2012]. | Revista medica de Chile | 2017 | name in abstract: Patria |
| PMID 29245600 | On the identity of Photophilus Folkmanová, 1928: A new generic synonymy (Chilopoda: Geophilomorpha: Geophilidae). | Zootaxa | 2017 | name in abstract: Patria |
| PMID 27346542 | Wnt, Frizzled, and sFRP gene expression patterns during gastrulation in the starfish Patiria (Asterina) pectinifera. | Gene expression patterns : GEP | 2016 | name in abstract: Patria |
| PMID 26701539 | True identity of Folkmanovius paralellus Dobroruka (Chilopoda: Geophilomorpha: Geophilidae). | Zootaxa | 2015 | name in abstract: Patria |
| PMID 22507409 | Pro patria et spes gentis: military medicine, paediatric surgery and those who care for children. | ANZ journal of surgery | 2011 | name in title: Patria |
| PMID 19172493 | Outpatient or inpatient stem cell transplantation: patria est ubicunque est bene? | Leukemia & lymphoma | 2009 | name in title: Patria |
| PMID 18952529 | [Assumption of medical risks and the problem of medical liability in ancient Roman law]. | Orvosi hetilap | 2008 | name in abstract: Patria |
| PMID 17242608 | Nontherapeutic quality improvement: The conflict of organizational ethics and societal rule of law. | Critical care medicine | 2007 | name in abstract: Patria |
| PMID 17967498 | Probabilistic risk assessment for linear alkylbenzene sulfonate (LAS) in sewage sludge used on agricultural soil. | Regulatory toxicology and pharmacology : RTP | 2007 | name in abstract: Patria |
| PMID 19522096 | Children of the patria: representations of childhood and welfare state ideologies at the 1922 Rio de Janeiro International Centennial Exposition. | Americas (Academy of American Franciscan History) | 2001 | name in title: Patria |
| PMID 2641957 | [Dental caries in preschoolers and students in Monte Patria, region 4]. | Odontologia chilena | 1989 | name in title: Patria |
| PMID 17269197 | New light on the patria of Arnald of Villanova. | Viator | 1982 | name in title: Patria |
| PMID 7189137 | Electron microscopic study of the cortical reaction in eggs of the starfish (Patria miniata). | Cell and tissue research | 1980 | name in title: Patria |
| PMID 5436268 | [Patria potestas and medical interventions affecting minor children]. | Minerva pediatrica | 1970 | name in title: Patria |
| PMID 14275616 | [THE "L. PATRIA" GERIATRIC INSTITUTE OF ALEXANDRIA. CONTRIBUTION TO THE SOLUTION OF A SOCIAL PROBLEM]. | Giornale di gerontologia | 1964 | name in title: Patria |
Notes
Live recombinant NDV-LaSota displaying a HexaPro prefusion-stabilised SARS-CoV-2 spike anchored by the NDV F transmembrane and cytoplasmic domains. Authorised for emergency use in Mexico as Patria (COFEPRIS, June 2024). The same construct is made under licence by other manufacturers (ButanVac in Brazil, HXP-GPOVac in Thailand); treated as one program per SPEC section 1 and those names are flagged ambiguous. Avimex also developed an inactivated presentation; the clinical trials cited here used the live vaccine.
How to cite
NDV-HXP-S (AXP000209.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000209.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.